Bothrops bites in Colombia: A multicenter study on the efficacy and safety of Antivipmyn-Tri®. A polyvalent antivenom produced in Mexico;Accidente bothrópico en Colombia: Estudio multicéntrico de la eficacia y seguridad de Antivipmyn-Tri®, un antiveneno polivalente producido en México

Iatreia

Volumn 20, Issue 3, 2007, Pages 244-262

  Otero Patiño, Rafael ^a   Silva Haad, Juan José ^b   Acevedo, María Jacqueline Barona ^a   Castaño, María Fabiou Toro ^a   Castillo, Juan Carlos Quintana ^a   Cadavid, Abel Díaz ^a   Vélez, Isabel Cristina Vásquez ^a   Rivera, Verónica Rodríguez ^a   Fiqueroa, Carlos Iván Delgado ^b   Ceballos, Manuel Fernández ^b   Audiber, Shirley Ayala ^c   Chaverra, Nectty Lorena Conrado ^c   Restrepo, Carlos Arturo Marín ^c   Giraldo, Coriolano Eugenio Ramírez ^d   Vides, Ana Berta Arrieta ^d   Julio, Elkin Aicardo Córdoba ^d   Zabaleta, Tania Isabel Ruiz ^e   Castañeda, María Vialó García ^e   Agudelo, Adriana Del Socorro Aguirre ^e   Guerra, John Jairo Londoño ^f   Bedoya, Natalia Ospina ^f   Prada, Diana María Macías ^f   Delgado, Oscar Fernando Jaramillo ^g   Agudelo, Hernán Darío Peláez ^g   Saldarriaga, María Eugenia Espinal ^g   Ballestas, Juan Manuel Camargo ^h   more..

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Hospital San Rafael   (Colombia)

^c Hospital San Francisco de Asís   (Colombia)

^d Hospital César Uribe Piedrahita   (Colombia)

^e Hospital La Cruz   (Colombia)

^f Hospital San Camilo de Lelis   (Colombia)

^g Hospital Regional Antonio Roldan B   (Colombia)

^h Hospital San Antonio   (Colombia)

Author keywords

Bothropic envenoming; Bothrops asper; Bothrops atrox; Colombia; Fabotherapy

Indexed keywords

ANTIVIPMYN TRI; SNAKE VENOM ANTISERUM; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COLOMBIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENVENOMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MEXICO; MULTICENTER STUDY; SNAKEBITE;

EID: 54249102133     PISSN: 01210793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Otero R, Tobón GS, Gómez LF, Osorio R, Valderrama R, Hoyos D, et al. Accidente ofídico en Antioquia y Chocó. Aspectos clínicos y epidemiológicos (marzo de 1989-febrero de 1990). Acta Med Colomb 1992; 17: 229-249.
2. Otero R, Gutiérrez J, Rodríguez O, Cárdenas SJ, Rodríguez L, Caro E, et al. Aspectos actuales de las mordeduras de serpientes en Colombia. Propuesta de intervención para un problema grave de salud en Antioquia y Chocó. Rev Epidemiol Antioquia 2001; 26: 43-48.
3. Otero R, Callejas ME, Gutiérrez J, Lotero GJ, Rodríguez O, Villa NH, et al. Necesidades reales de antivenenos en Colombia. Características de los productos y del mercado. Rev Epidemiol Antioquia 2001; 26: 49-59.
4. Silva- Haad JJ. Las serpientes del género Bothrops en la Amazonía colombiana. Acta Med Colomb 1989; 14: 148-165.
5. Campbell JA, Lamar WW. The Venomous Reptiles of the Western Hemisphere. Ithaca (NY): Cornell University Press; 2004.
6. Otero R, Valderrama R, Osorio RG, Posada LE. Programa de atención primaria del accidente ofídico. Una propuesta para Colombia. Iatreia 1992; 5: 96-102.
7. Otero R, Gutiérrez JM, Núñez V, Robles A, Estrada R, Segura E, et al. A randomized double-blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in Colombia. Trans R Soc Trop Med Hyg 1996; 90: 696-700.
8. Otero R, Gutiérrez JM, Rojas G, Núñez V, Díaz A, Miranda E, et al. A randomized blind clinical trial of two antivenoms prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia. Correlation between safety and biochemical characteristics of antivenoms. Toxicon 1999; 37: 895-908.
9. Otero-Patiño R, Cardoso JLC, Higashi HG, Núñez V. Díaz A, Toro MF, et al. A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Urabá, Colombia. Am J Trop Med Hyg 1998; 58: 183-189.
10. Ayres JA, Barraviera B. Evaluation of the intradermal sensitivity test in patients submitted to heterologous serotheraphy. J Venom Anim Toxins 1999; 5: 142-152.
11. Bon C. The serum-therapy was discovered 100 years ago. Toxicon 1996; 34: 142-143.
12. st ed. Chichester: John Wiley & Sons; 1997. p. 205-221.
13. 2 myotoxins. Toxicon 1999; 37: 199-215.
14. Lomonte B, Lundgren J, Johansson B, Bagge U. The dynamics of local tissue damage induced by Bothrops asper snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron miocroscopic study. Toxicon 1994; 32: 41-55.
15. Gutiérrez JM, León G, Rojas G, Lomonte B, Rucavado A, Chaves F. Neutralization of local tissue damage induced by Bothrops asper (terciopelo) snake venom. Toxicon 1998; 36: 1529-1538.
16. León G, Valverde Jm, Rojas G, Lomonte B, Gutiérrez JM. Comparative study on the ability of IgG and Fab sheep antivenoms to neutralize local hemorrhage, edema and myonecrosis induced by Bothrops asper (terciopelo) snake venom. Toxicon 2000; 38: 233-244.
17. León G, Mongue M, Rojas E, Lomonte B, Gutiérrez JM. Comparison between IgG and F(ab′)2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions. Toxicon 2001; 39: 793-801.
18. Chippaux JP, Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 1998; 36: 823-846.
19. 2 o Fab en picaduras de escorpiones y mordeduras de serpientes. Pediatría 2002; 37: 8-16.
20. Otero R, Núñez V, Barona J, Díaz A, Saldarriaga M. Características bioquímicas y capacidad neutralizante de cuatro antivenenos polivalentes frente a los efectos farmacológicos y enzimáticos del veneno de Bothrops asper y Porthidium nasutum de Antioquia y Chocó. Iatreia 2002; 15: 5-15.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
22. WORLD HEALTH ORGANIZATION. Progress in the Characterization of Venoms and Standardization of Antivenoms. WHO Offset Publication 1981; 58: 1-44.
23. a ed. Universidad de Costa Rica; 1990.
24. Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951; 37: 316-320.
25. a ed. São Paulo: Sarvier; 1992. p. 176-181.
26. Malasit P, Warrell DA, Chantavanich P, Viravan C, Mongkilsapaya J, Singhthong B, et al. Prediction, prevention and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br Med J 1986; 292: 17-20.
27. Ho M, Warrell Da, Looareesuwan S, Phillips RE, Chanthavanich P, Karbwang J, et al. Clinical significance of venom antigen levels in patients envenomed by the Malayan pit viper (Calloselasma rhodostoma). Am J Trop Med Hyg 1986; 35: 579-587.
28. Sano-Martins IS, Fan HW, Castro SCB, Tomy SC, França FOS, Jorge MT, et al. Reliability of the simple 20 minute whole blood clotting test (WBCT20) as an indicator of low plasma fibrinogen concentration in patients envenomed by Bothrops snakes. Toxicon 1994; 32: 1045-1050.
29. st ed. Boca Ratón: CRC Press; 1995. p. 493-594.
30. Theakston RDG, Lloyd-Jones MJ, Reid HA, Micro-ELISA for detecting and assaying snake venom and venom antibody. Lancet 1977; 2: 639-641.
31. Theakston RDG, Fan HW, Warrell DA, Dias DA Silva WD, Ward SA, Higashi HG, et al. Use of enzyme immunoassays to compare the effect and assess the dosage regimens of three Brazilian Bothrops antivenoms. Am J Trop Med Hyg 1992; 47: 593-604.
32. Barraviera B, Sartori A, Pereira DA Silva MF, Kaneo R, Peracolli MTS. Use of an Elisa assay to evaluate venom, antivenom, IgG and IgM human antibody levels in serum and cerebrospinal fluid from patients bitten by Crotalus durissus terrificus in Brazil. J Venom Anim Toxins 1996; 2: 14-27.
33. Theakston RDG, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003; 41: 541-557.
34. Kamiguti AS, Cardoso JLC. Haemostatic changes caused by venoms of South American snakes. Toxicon 1989; 27: 955-963.
35. Kamiguti AS, Hay CRM, Theakston RDG, Zuzel M. Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. Toxicon 1996; 34: 627-642.
36. Escalante T, Núñez J, Moura DA Silva AM, Rucavado A, Theakston RDG, Gutiérrez JM. Pulmonary hemorrhage induced by jararhagin, a metalloproteinase from Bothropsjararaca snake venom. Toxicol Appl Pharmacol 2003; 193: 17-28.
37. Escalante T, Rucavado A, Kamiguti AS, Theakston RDG, Gutiérrez JM. Bothrops asper metalloproteinase BaP1 is inhibited by alfa 2-macroglobulin and mouse serum and does not induce systemic hemorrhage or coagulopathy. Toxicon 2004; 43: 213-217.
38. Otero R, Gutiérrez J, Mesa MB, Duque E, Rodríguez O, Arango JL, et al. Complications of Bothrops, Porthidium and Bothriechis snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in an university hospital. Toxicon 2002; 40: 1107-1114.
39. Warrell DA, Looareesuwan S, Theakston RDG, Phillips RE, Chanthavanich P, Viravan C, et al. Comparative trial of three monospecific antivenoms for bites by the Malayan Pit viper (Calloselasma rhodostoma) in Southern Thailand; clinical and laboratory correlations. Am J Trop Med Hyg 1986; 35: 1235-1247.
40. 2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators. Trans R Soc Trop Med Hyg 1998; 92: 657-662.
41. Dart RC, Macnally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37: 181-188.
42. Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med 2001; 37: 189-195.
43. Boyer LV, Seifert SA, Cain JS. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom. Ann Emerg Med 2001; 37: 196-201.
44. Ho M, Silamut K, White NJ, Karbwang J, Looareesuwan S, Phillips RE, et al. Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg 1990; 42: 260-266.
45. Lalloo DG, Theakston RDG. Snake antivenoms. J Toxicol Clin Toxicol 2003; 41: 277-290.
46. a ed. Medellín: CIB; 2001. p. 571-578.
47. Henderson A, Baldwin LN, May C. Fatal brown snake (Pseudonaja textilis) envenomation despite the use of antivenom. Med J Aust 1993; 158: 709-710.
48. Masci PP, Mirtschin PJ, Nias TN, Turnbull RK, Kuchel TR, Whitaker AN. Brown snakes (Pseudonaja genus): venom yields, prothrombin activator neutralization and implications affecting antivenom usage. Anaesth Intensive Care 1998; 26: 276-281.
49. Markland FS. Snake venoms and the hemostatic system. Toxicon 1998; 36: 1749-1800.
50. a ed. São Paulo: Sarvier: 2003. p. 289-309.
51. a ed. São Paulo: Sarvier; 2003. p. 310-323.
52. García M, Monge M, León G, Lizano S, Segura E, Solano G, et al. Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation. Biologicals 2002; 30: 143-151.
53. Jurkovich GJ, Luterman A, Mccullar K, Ramenofsky ML, Curreri PW. Complications of Crotalidae antivenin therapy. J Trauma 1988; 28: 1032-1037.
54. Cupo P, Azevedo-Marques MM, De Menezes JB, Hering SE. Reaçoes de hipersensibilidade imediatas apos uso intravenoso de soros antivenenos: valor prognistico dos testes de sensibilidade intradermicos. Rev Inst Med Trop São Paulo 1991; 33: 115-122.
55. Cardoso JLC, Fan HW, França FOS, Jorge MT, Leite SA, Nishioka SA, et al. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil. Q J Med 1993; 56: 315-325.
56. Teixeira-Caiaffa W, Vlahov D, Figueiredo-Antunes CM, Ramos De Oliveira H, Diniz CR. Snake bite and antivenom complications in Belo Horizonte, Brazil. Trans R Soc Trop Med Hyg 1994; 88: 81-85.
57. Smith DC, Reddi KR, Laing G, Theakston RDG, Landon J. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 1992; 30: 865-871.
58. Sutherland SK. Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits. Med J Aust 1992; 157: 734-739.
59. Karlson-Stiber C, Persson H. Antivenom treatment in Vipera berus envenoming: report of 30 cases. J Intern Med 1994; 235: 57-61.
60. Kirkpatrick CH. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. Am J Emerg Med 1991; 9 (Suppl. 1): 7-10.
61. Pardal PPO, Souza SM, Monteiro MRCC, Fan HW, Cardoso JLC, França FOS, et al. Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans R Soc Trop Med Hyg 2004; 98: 28-42.
62. Rawat S, Laing G, Smith DC, Theakston RDG, Landon J. A new antivenom to treat Eastern Coral snake (Micrurusfulviusfulvius) envenoming. Toxicon 1994; 32: 185-190.
63. Rojas G, Jiménez JM, Gutiérrez JM. Caprylic acid fractionation of hyperimmune horse plasma. Description of a simple procedure for antivenom production. Toxicon 1994; 32: 351-363.
64. 2 fragments. Toxicon 1994; 32: 725-734
65. Chippaux JP. The development and use of immunotherapy in Africa. Toxicon 1998; 36: 1503-1506.
66. Smalligan R, Cole J, Brito N, Laing GD, Mertz BL, Manock S, et al. Crotaline snake bite in the Ecuadorian Amazon: randomized double blind comparative trial of three South American polyspecific antivenoms. Br Med J 2004; 329: 1129-1135.